Drug Trial Radar · NCT07916480
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
415
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Apr 27, 2028
Study completion Mar 28, 2029
Sponsor
- Lead sponsor
- Arcutis Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study is designed to evaluate the efficacy and safety of once-daily roflumilast cream 0.3% in children, adolescents, and adults with moderate to severe atopic dermatitis. Approximately 415 participants will be randomized in a 2:1 ratio to receive roflumilast cream 0.3% or matching vehicle cream during a 4-week double-blind, vehicle-controlled treatment period. Following completion of the double-blind treatment period, all participants will enter a 48-week open-label extension and receive roflumilast cream 0.3%. The study will assess the efficacy of roflumilast cream 0.3% in improving signs and symptoms of atopic dermatitis and evaluate its long-term safety and tolerability through Week 52.
Conditions
- Atopic Dermatitis
- Atopic Dermatitis (AD)
- Atopic Dermatitis (Eczema)
Interventions
Roflumilast Cream 0.3%Drug
Roflumilast cream 0.3% administered topically once daily to affected areas during the 4-week double-blind treatment period. Participants may continue treatment with roflumilast cream 0.3% during the 48-week open-label extension.
Vehicle CreamDrug
Matching vehicle cream administered topically once daily to affected areas during the 4-week double-blind treatment period. Participants will receive roflumilast cream 0.3% during the open-label extension phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Achievement of vIGA-AD Success at Week 4Time frame: Week 4
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Arcutis Site 324
Birmingham, Alabama · Recruiting
Arcutis Site 337
Bryant, Arkansas · Recruiting
Arcutis Site 321
Miami Lakes, Florida · Recruiting
Arcutis Site 320
Chicago, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.